419 related articles for article (PubMed ID: 8943316)
1. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.
Adams PD; Sellers WR; Sharma SK; Wu AD; Nalin CM; Kaelin WG
Mol Cell Biol; 1996 Dec; 16(12):6623-33. PubMed ID: 8943316
[TBL] [Abstract][Full Text] [Related]
2. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
3. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
4. The amino terminus of Cdk2 binds p21.
Moskowitz NK; Borao FJ; Dardashti O; Cohen HD; Germino FJ
Oncol Res; 1996; 8(9):343-52. PubMed ID: 8979268
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases.
Wohlschlegel JA; Dwyer BT; Takeda DY; Dutta A
Mol Cell Biol; 2001 Aug; 21(15):4868-74. PubMed ID: 11438644
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-binding motifs are essential for the function of p21CIP1.
Chen J; Saha P; Kornbluth S; Dynlacht BD; Dutta A
Mol Cell Biol; 1996 Sep; 16(9):4673-82. PubMed ID: 8756624
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
8. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.
Castaño E; Kleyner Y; Dynlacht BD
Mol Cell Biol; 1998 Sep; 18(9):5380-91. PubMed ID: 9710622
[TBL] [Abstract][Full Text] [Related]
9. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
[TBL] [Abstract][Full Text] [Related]
10. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes.
Lacy S; Whyte P
Oncogene; 1997 May; 14(20):2395-406. PubMed ID: 9188854
[TBL] [Abstract][Full Text] [Related]
11. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.
Adams PD; Li X; Sellers WR; Baker KB; Leng X; Harper JW; Taya Y; Kaelin WG
Mol Cell Biol; 1999 Feb; 19(2):1068-80. PubMed ID: 9891042
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
[TBL] [Abstract][Full Text] [Related]
13. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
14. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression.
Hall C; Nelson DM; Ye X; Baker K; DeCaprio JA; Seeholzer S; Lipinski M; Adams PD
Mol Cell Biol; 2001 Mar; 21(5):1854-65. PubMed ID: 11238922
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
16. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Carroll JS; Prall OW; Musgrove EA; Sutherland RL
J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
18. Differences in substrate specificity between Cdk2-cyclin A and Cdk2-cyclin E in vitro.
Higashi H; Suzuki-Takahashi I; Taya Y; Segawa K; Nishimura S; Kitagawa M
Biochem Biophys Res Commun; 1995 Nov; 216(2):520-5. PubMed ID: 7488142
[TBL] [Abstract][Full Text] [Related]
19. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
